Miragen Therapeutics, Inc.
(NASDAQ : MGEN)

( )
MGEN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. 1.14%67.561.0%$1024.31m
BIIBBiogen, Inc. -0.37%333.001.5%$704.38m
AMGNAmgen, Inc. 0.20%223.481.3%$582.04m
ILMNIllumina, Inc. 2.59%298.923.5%$424.29m
REGNRegeneron Pharmaceuticals, Inc. 0.19%399.552.6%$378.07m
VRTXVertex Pharmaceuticals, Inc. 1.55%243.821.9%$358.57m
ALXNAlexion Pharmaceuticals, Inc. -0.83%102.562.0%$204.52m
EXASEXACT Sciences Corp. 3.61%98.1824.0%$177.12m
AAgilent Technologies, Inc. 0.43%85.841.6%$157.99m
SGENSeattle Genetics, Inc. -0.13%118.076.1%$115.03m
MRNAModerna, Inc. -0.24%19.000.0%$108.13m
INCYIncyte Corp. 0.51%78.452.5%$101.70m
SRPTSarepta Therapeutics, Inc. 0.31%125.4214.6%$97.52m
BMRNBioMarin Pharmaceutical, Inc. 0.87%89.014.3%$96.71m
XLRNAcceleron Pharma, Inc. -0.48%93.666.1%$94.41m

Company Profile

Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.